415 Capital Management

415 Capital Management
Widenmayerstrasse 15 | 80538 München | de


415 Capital Management GmbH is a specialist investment firm which invests in innovative medical device (“MedTech”) companies in Europe, the United States, and Israel. The firm primarily invests in novel technologies addressing cardiovascular disease, its risk factors and comorbidities. The 415 Capital team has funded over 50 MedTech startups over the past 25 years with successful exits including Claret Medical (sold to Boston Scientific), ReCor Medical (sold to Otsuka Holdings), ImThera Medical (sold to LivaNova), CardiAQ Valve Technologies (sold to Edwards Lifesciences), and CoreValve (sold to Medtronic).


Name der Ansprechpartner
Frederik Groenewegen
Managing Directors / Partners Frank Groenewegen
David Thompson
Frederik Groenewegen
Shareholders Frank Groenewegen
David Thompson
Frederik Groenewegen
Professionals 415 Capital Management GmbH
Fund Count 2
Capital € 100 m
Portfolio Companies 10-15
Investment Type Unabhängige Beteiligungsgesellschaft
Equity / Investment range 4.000 Mio. € - 10.000 Mio. €
Transaction volume 1 Mio. € - 5 Mio. €
Equity Type Minderheitsbeteiligung
Investment Reasons Seed-Finanzierung
Start up-Finanzierung
Expansions- / Wachstumsfinanzierung
Bridge- / vorbörsliche Finanzierung
Industry sector Medizin - Healthcare
Geographical Focus Deutschland
Deutschsprachiger Raum (DACH)